Intrinsiqq
Venus Concept Inc. logo

Venus Concept Inc. Quality Score

VERO

⊜ Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Revenue Growth
0/100
-13.6%

Below 2%, essentially flat

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
100/100
-62.5%

Shrinking >2%, active buybacks

Margin Trend
0/100
-45.0pp

Contracted >2pp, margin pressure

Capital Structure
0/100
$28M

Positive debt with no FCF to service it

2021
$31.0M
$77.0M
2022
$12.0M
$76.0M
2023
$5.00M
$76.0M
2024
$4.00M
$43.0M
TTM
$4.00M
$33.0M
CashDebt
Return on Capital
0/100
-68.2%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

SourceQuality score computed from the 10-Q filed 7 Nov 2025, covering the period ending 30 Sept 2025, as reported to the SEC. Data last refreshed 8 Jun 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with VERO

CompareIntrinsic value
CVRXCVRx, Inc.
$1.58+14.49%40
LNSRLensar Inc.
$5.84+4.85%40
CARLCarlsmed, Inc.
$16.09+11.74%44
APYXApyx Medical Corporation
$2.59-0.38%26
SIShoulder Innovations, Inc.
$21.01+6.00%35
SSIISS Innovations International, Inc.
$2.27-2.58%40
PDEXPro-Dex Inc.
$63.44+5.31%86
RCELAvita Medical Inc.
$16.32+6.46%30

Spot a number that looks wrong? Check it in VERO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing VERO

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.